Vinva Investment Management Ltd Has $563,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Vinva Investment Management Ltd reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 15.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,946 shares of the biopharmaceutical company’s stock after selling 3,647 shares during the quarter. Vinva Investment Management Ltd’s holdings in Royalty Pharma were worth $563,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of RPRX. Versant Capital Management Inc grew its holdings in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,043 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Royalty Pharma during the 2nd quarter worth approximately $32,000. Blue Trust Inc. grew its position in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares in the last quarter. Finally, Transamerica Financial Advisors Inc. boosted its stake in shares of Royalty Pharma by 99.9% in the third quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,729 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on RPRX. Citigroup lowered their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. The Goldman Sachs Group boosted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Trading Up 0.2 %

RPRX opened at $26.66 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. Royalty Pharma plc has a fifty-two week low of $25.10 and a fifty-two week high of $31.66. The company’s 50 day moving average price is $27.15 and its two-hundred day moving average price is $27.32. The firm has a market capitalization of $15.71 billion, a price-to-earnings ratio of 13.81, a PEG ratio of 4.67 and a beta of 0.47.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.